Pluri Inc. (NASDAQ:PLUR) Sees Large Increase in Short Interest

Pluri Inc. (NASDAQ:PLUR) was the target of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 22,147 shares, an increase of 22.7% from the January 15th total of 18,051 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average daily trading volume, of 10,055 shares, the days-to-cover ratio is currently 2.2 days. Based on an average daily trading volume, of 10,055 shares, the days-to-cover ratio is currently 2.2 days. Approximately 0.3% of the company’s shares are sold short.

Institutional Trading of Pluri

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC purchased a new stake in Pluri Inc. (NASDAQ:PLUR) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri at the end of the most recent reporting period. 16.59% of the stock is owned by institutional investors and hedge funds.

Pluri Price Performance

Shares of PLUR opened at $3.66 on Tuesday. The company has a market cap of $36.73 million, a PE ratio of -0.74 and a beta of 0.67. The stock has a 50-day moving average of $3.26 and a 200-day moving average of $3.98. Pluri has a one year low of $2.82 and a one year high of $7.13.

Pluri (NASDAQ:PLUR) last released its quarterly earnings data on Thursday, February 12th. The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.06). The company had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.64 million.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pluri in a research report on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Pluri has a consensus rating of “Hold” and an average target price of $12.00.

Pluri Company Profile

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.